Wednesday, October 22, 2014 Last update: 5:33 PM
FreshNews.com - Covering Large & Obscure Tech Companies Since 1996

Alcresta Appoints John H. Tucker to Chief Executive Officer

Companies mentioned in this article: Alcresta

NEWTON, Mass. -- (BUSINESS WIRE) -- Alcresta®, a leading medical nutrition company developing innovative enzyme-based products for individuals with unique nutritional needs battling acute conditions or chronic diseases, today announced the appointment of John H. Tucker as chief executive officer. Mr. Tucker, former senior vice president and chief commercial officer of Incline Therapeutics, brings to Alcresta more than 20 years of commercial experience in the biotechnology and pharmaceutical industries and has successfully led numerous product launches. Co-founder and former CEO Alexey Margolin, Ph.D., will be chairman of the company’s board of directors.

“John has both the strong leadership skills and the commercial expertise required to successfully position Alcresta for the launch of our point-of-care nutritional products, including our lead product designed to improve the digestion and absorption of omega-3 in compromised patients,” said Alexey Margolin, chairman of the board for Alcresta. “John’s experience building commercial ready infrastructures in both private and public companies, as well as developing new markets, will be hugely beneficial to Alcresta as we advance our lead program and continue the transition to a commercial-stage organization.”

Prior to Alcresta, Mr. Tucker served as senior vice president and chief commercial officer of Incline Therapeutics, a hospital-focused specialty pharmaceutical company. There, he developed and drove the overall commercial strategy in support of the company’s lead product, IONSYS, resulting in a $390 million purchase of Incline by The Medicines Company. He joined Incline from AMAG Pharmaceuticals, where he was senior vice president, commercial operations, responsible for all sales and marketing activities for the company. Previously, as president, U.S. operations at Basilea Pharmaceuticals, Mr. Tucker developed the strategy and organization for the planned launch of a hospital-focused product and led the company’s commercial development team. Prior to Basilea, Mr. Tucker was executive vice president, sales and marketing at Indevus Pharmaceuticals. Earlier in his career, he held a variety of both hospital and retail-based sales and marketing positions with increasing levels of responsibility at Ortho-McNeil Pharmaceuticals, ALZA Corporation, VIVUS and UCB Pharma. Mr. Tucker holds a B.A. from Plymouth State College and an MBA from New Hampshire College.

“I am thrilled to join Alcresta at this exciting time in the company’s development, and I believe that the company’s lead product has the potential to improve proper nutrition in the management of acute and chronic diseases, ultimately making a meaningful difference for patients in need,” said Mr. Tucker. “The team, led by Alex and Bob, have already made dramatic progress advancing the technology, our lead product and achieving a number of significant corporate milestones, and I look forward to working with both of them and the broader team as we plan for Alcresta’s next stage of growth.”

About Alcresta

Alcresta is a leading medical nutrition company developing and commercializing innovative enzyme-based point-of-care products to improve the digestion and absorption of key nutrients to support growth, development and nutrition in people battling acute conditions or chronic diseases. The demand for high-value nutritional products is increasing, driving the growth of a $40 billion global market. While there have been important recent advances in nutritional drinks and products, there remains a significant need for enzyme-based nutritional products that support healthier living, maximize nutrient and caloric absorption, and complement conventional medical care. Leveraging its existing proprietary platform of point-of-care nutritional products, Alcresta has developed a lead product designed to improve the digestion and absorption of fats, in particular long-chain polyunsaturated fatty acids like omega-3 (including DHA, EPA). The importance of long-chain polyunsaturated fatty acids like omega-3 is well documented across the full spectrum of patient care from infants to adults and individuals battling acute conditions or chronic diseases. The company’s platform is supported by the Alcresta team’s extensive experience in pharmaceutical and nutritional product development. Based in Newton, Mass., the company is backed by top-tier venture investors Bessemer Venture Partners, Frazier Healthcare and Third Rock Ventures. For more information, please visit www.alcresta.com.


Copyright © Business Wire 2014
Contact:

Alcresta, Inc.
Robert Gallotto, President
617-916-1207
or
Media Contact:
Pure Communications Inc.
Dan Budwick, 973-271-6085